Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans.

Kohli U, Hahn MK, English BA, Sofowora GG, Muszkat M, Li C, Blakely RD, Stein CM, Kurnik D.

Pharmacogenet Genomics. 2011 Apr;21(4):171-8. doi: 10.1097/FPC.0b013e328344f63e.

2.

Association between major depressive disorder and the norepinephrine transporter polymorphisms T-182C and G1287A: a meta-analysis.

Zhao X, Huang Y, Ma H, Jin Q, Wang Y, Zhu G.

J Affect Disord. 2013 Aug 15;150(1):23-8. doi: 10.1016/j.jad.2013.03.016. Review.

PMID:
23648227
3.

Norepinephrine transporter polymorphisms T-182C and G1287A are not associated with alcohol dependence and its clinical subgroups.

Huang SY, Lu RB, Ma KH, Shy MJ, Lin WW.

Drug Alcohol Depend. 2008 Jan 1;92(1-3):20-6.

PMID:
17630229
4.

[Association between norepinephrine transporter gene polymorphism and alcohol dependence in Japanese].

Narita S, Nagahori K, Nishizawa D, Yoshihara E, Kawai A, Murayama O, Ikeda K, Iwahashi K.

Nihon Arukoru Yakubutsu Igakkai Zasshi. 2014 Dec;49(6):330-9. Japanese.

PMID:
25831948
5.

Catecholamine pathway gene variation is associated with norepinephrine and epinephrine concentrations at rest and after exercise.

Ghimire LV, Kohli U, Li C, Sofowora GG, Muszkat M, Friedman EA, Solus JF, Wood AJ, Stein CM, Kurnik D.

Pharmacogenet Genomics. 2012 Apr;22(4):254-60. doi: 10.1097/FPC.0b013e328350a274.

6.

The role of catecholamines, age, and fitness on blood pressure reactivity to dynamic exercise in patients with essential hypertension.

Braun LT, Potempa K, Holm K, Fogg L, Szidon JP.

Heart Lung. 1994 Sep-Oct;23(5):404-12.

PMID:
7989209
7.

The combined effect of norepinephrine transporter gene and negative life events in major depression of Chinese Han population.

Sun N, Xu Y, Wang Y, Duan H, Wang S, Ren Y, Peng J, Du Q, Shen Y, Xu Q, Zhang K.

J Neural Transm (Vienna). 2008 Dec;115(12):1681-6. doi: 10.1007/s00702-008-0109-5.

PMID:
18779921
8.

No evidence for association between a functional promoter variant of the Norepinephrine Transporter gene SLC6A2 and ADHD in a family-based sample.

Renner TJ, Nguyen TT, Romanos M, Walitza S, Röser C, Reif A, Schäfer H, Warnke A, Gerlach M, Lesch KP.

Atten Defic Hyperact Disord. 2011 Sep;3(3):285-9. doi: 10.1007/s12402-011-0060-4.

PMID:
21739117
9.

Association between norepinephrine transporter T-182C polymorphism and major depressive disorder: a meta-analysis.

Zhou Y, Su H, Song J, Guo L, Sun Y.

Neurosci Lett. 2014 Feb 21;561:64-8. doi: 10.1016/j.neulet.2013.12.035.

PMID:
24374057
10.

Genetic variations in the α(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine.

Kurnik D, Muszkat M, Li C, Sofowora GG, Friedman EA, Scheinin M, Wood AJ, Stein CM.

Circ Cardiovasc Genet. 2011 Apr;4(2):179-87. doi: 10.1161/CIRCGENETICS.110.957662.

11.

Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression.

Kautto M, Kampman O, Mononen N, Lehtimäki T, Haraldsson S, Koivisto PA, Leinonen E.

Neurosci Lett. 2015 Mar 17;590:116-20. doi: 10.1016/j.neulet.2015.01.077.

PMID:
25650523
12.

Cardiovascular and plasma catecholamine responses to exercise in blacks and whites.

Walker AJ, Bassett DR Jr, Duey WJ, Howley ET, Bond V, Torok DJ, Mancuso P.

Hypertension. 1992 Oct;20(4):542-8.

13.

Chronic depolarization stimulates norepinephrine transporter expression via catecholamines.

Habecker BA, Willison BD, Shi X, Woodward WR.

J Neurochem. 2006 May;97(4):1044-51.

14.

Increased blood pressure and hyperdynamic cardiovascular responses in carriers of a common hyperfunctional variant of adenylyl cyclase 6.

Hodges GJ, Gros R, Hegele RA, Van Uum S, Shoemaker JK, Feldman RD.

J Pharmacol Exp Ther. 2010 Nov;335(2):451-7. doi: 10.1124/jpet.110.172700.

15.

SERT and NET polymorphisms, temperament and antidepressant response.

Andre K, Kampman O, Illi A, Viikki M, Setälä-Soikkeli E, Mononen N, Lehtimäki T, Haraldsson S, Koivisto PA, Leinonen E.

Nord J Psychiatry. 2015;69(7):531-8. doi: 10.3109/08039488.2015.1012554.

PMID:
25739526
16.

Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder.

Park S, Kim JW, Yang YH, Hong SB, Park MH, Kim BN, Shin MS, Yoo HJ, Cho SC.

Behav Brain Funct. 2012 May 16;8:22. doi: 10.1186/1744-9081-8-22.

17.

Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.

Cho SC, Kim BN, Cummins TD, Kim JW, Bellgrove MA.

J Psychopharmacol. 2012 Mar;26(3):380-9. doi: 10.1177/0269881111405356.

PMID:
21628343
18.

Novel and functional norepinephrine transporter protein variants identified in attention-deficit hyperactivity disorder.

Hahn MK, Steele A, Couch RS, Stein MA, Krueger JJ.

Neuropharmacology. 2009 Dec;57(7-8):694-701. doi: 10.1016/j.neuropharm.2009.08.002.

19.

Lack of association between the norepinephrine transporter gene and major depression in a Han Chinese population.

Chang CC, Lu RB, Chen CL, Chu CM, Chang HA, Huang CC, Huang YL, Huang SY.

J Psychiatry Neurosci. 2007 Mar;32(2):121-8.

20.

Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy.

Nonen S, Okamoto H, Fujio Y, Takemoto Y, Yoshiyama M, Hamaguchi T, Matsui Y, Yoshikawa J, Kitabatake A, Azuma J.

Pharmacogenomics J. 2008 Feb;8(1):78-84.

PMID:
17404580

Supplemental Content

Support Center